169 related articles for article (PubMed ID: 38493698)
1. Elevated expression of LCN13 through FXR activation ameliorates hepatocellular lipid accumulation and inflammation.
Qin X; Tan Y; Ren W; Zhou W; Niu R; Liang L; Li J; Cao K; Wei G; Zhu X; Huang M
Int Immunopharmacol; 2024 Apr; 131():111812. PubMed ID: 38493698
[TBL] [Abstract][Full Text] [Related]
2. Lipocalin 13 protein protects against hepatic steatosis by both inhibiting lipogenesis and stimulating fatty acid β-oxidation.
Sheng L; Cho KW; Zhou Y; Shen H; Rui L
J Biol Chem; 2011 Nov; 286(44):38128-38135. PubMed ID: 21908604
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA
Xie Y; Huang Y; Li ZY; Jiang W; Shi NX; Lu Y; Cao G; Yin Z; Lin XJ
Mol Cancer; 2024 May; 23(1):95. PubMed ID: 38720319
[TBL] [Abstract][Full Text] [Related]
4. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
[TBL] [Abstract][Full Text] [Related]
5. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
[TBL] [Abstract][Full Text] [Related]
6. Ablation of IFNγ in myeloid cells suppresses liver inflammation and fibrogenesis in mice with hepatic small heterodimer partner (SHP) deletion.
Zhu L; Litts B; Wang Y; Rein JA; Atzrodt CL; Chinnarasu S; An J; Thorson AS; Xu Y; Stafford JM
Mol Metab; 2024 May; 83():101932. PubMed ID: 38589002
[TBL] [Abstract][Full Text] [Related]
7. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
8. Lipocalin 13 regulation of glucose and lipid metabolism in obesity.
Zhou Y; Rui L
Vitam Horm; 2013; 91():369-83. PubMed ID: 23374724
[TBL] [Abstract][Full Text] [Related]
9. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
[TBL] [Abstract][Full Text] [Related]
10. Krüppel-like factor 10 protects against metabolic dysfunction-associated steatohepatitis by regulating HNF4α-mediated metabolic pathways.
Pan X; Hu S; Xu Y; Gopoju R; Zhu Y; Cassim Bawa FN; Wang H; Wang J; Batayneh Z; Clark A; Zeng Y; Lin L; Wang X; Yin L; Zhang Y
Metabolism; 2024 Jun; 155():155909. PubMed ID: 38582490
[TBL] [Abstract][Full Text] [Related]
11. Lipocalin-13 regulates glucose metabolism by both insulin-dependent and insulin-independent mechanisms.
Cho KW; Zhou Y; Sheng L; Rui L
Mol Cell Biol; 2011 Feb; 31(3):450-7. PubMed ID: 21135134
[TBL] [Abstract][Full Text] [Related]
12. Lipocalin 13 enhances insulin secretion but is dispensable for systemic metabolic control.
Bühler L; Maida A; Vogl ES; Georgiadi A; Takacs A; Kluth O; Schürmann A; Feuchtinger A; von Toerne C; Tsokanos FF; Klepac K; Wolff G; Sakurai M; Ekim Üstünel B; Nawroth P; Herzig S
Life Sci Alliance; 2021 Apr; 4(4):. PubMed ID: 33536239
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor.
Xu W; Cui C; Cui C; Chen Z; Zhang H; Cui Q; Xu G; Fan J; Han Y; Tang L; Targher G; Byrne CD; Zheng MH; Yang L; Cai J; Geng B
Hepatology; 2022 Dec; 76(6):1794-1810. PubMed ID: 35586979
[TBL] [Abstract][Full Text] [Related]
14. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor.
Liu M; Zhang G; Wu S; Song M; Wang J; Cai W; Mi S; Liu C
J Ethnopharmacol; 2020 Jun; 255():112776. PubMed ID: 32205261
[TBL] [Abstract][Full Text] [Related]
15. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.
Salvoza N; Giraudi P; Gazzin S; Bonazza D; Palmisano S; de Manzini N; Zanconati F; Raseni A; Sirianni F; Tiribelli C; Rosso N
J Transl Med; 2023 Dec; 21(1):906. PubMed ID: 38082368
[TBL] [Abstract][Full Text] [Related]
16. Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.
Bendixen SM; Jakobsgaard PR; Hansen D; Hejn KH; Terkelsen MK; Bjerre FA; Thulesen AP; Eriksen NG; Hallenborg P; Geng Y; Dam TV; Larsen FT; Wernberg CW; Vijayathurai J; Scott EAH; Marcher AB; Detlefsen S; Grøntved L; Dimke H; Berdeaux R; de Aguiar Vallim TQ; Olinga P; Lauridsen MM; Krag A; Blagoev B; Ravnskjaer K
J Hepatol; 2024 Mar; 80(3):467-481. PubMed ID: 37972658
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice.
Ma KL; Ruan XZ; Powis SH; Chen Y; Moorhead JF; Varghese Z
Hepatology; 2008 Sep; 48(3):770-81. PubMed ID: 18752326
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte Deubiquitinating Enzyme OTUD5 Deficiency is a Key Aggravator for Metabolic Dysfunction-Associated Steatohepatitis by Disturbing Mitochondrial Homeostasis.
Dai J; Zhang L; Zhang R; Ge J; Yao F; Zhou S; Xu J; Yu K; Xu J; Jiang L; Jin K; Dai X; Li J; Li Q
Cell Mol Gastroenterol Hepatol; 2024; 17(3):399-421. PubMed ID: 38036082
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis antagonizing transcription factor-mediated liver damage and inflammation to cancer: Therapeutic intervention by curcumin in experimental metabolic dysfunction associated steatohepatitis-hepatocellular carcinoma.
Srinivas AN; Suresh D; Chidambaram SB; Santhekadur PK; Kumar DP
J Cell Physiol; 2024 Jan; 239(1):135-151. PubMed ID: 37942831
[TBL] [Abstract][Full Text] [Related]
20. Hepatoprotective effect of Typhaneoside on non-alcoholic fatty liver disease via farnesoid X receptor in vivo and in vitro.
Zheng Y; Zhao J; Miao D; Xu T; Wang L; Liu C; Gao Y; Yu L; Shen C
Biomed Pharmacother; 2023 Aug; 164():114957. PubMed ID: 37295248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
